MCRB

Seres Therapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.93
52-Week Range: $2.83 – $29.98
Market Cap: $29.53M
P/E (TTM): —
EPS (TTM): -2.42
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.84
PEG Ratio: —
Return on Equity: -66.57%
Return on Assets: -39.85%
Gross Margin: 0.00%
Operating Margin: -2101.36%
Profit Margin: 0.00%
Current Ratio: 2.11
Debt/Equity: 1.64
Total Debt: $56.64M
Free Cash Flow: $-64.60M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $70.28M

MCRB Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$789.00K
Cost of Revenue	$0.00	$0.00	$3.53M	$6.54M
Gross Profit	$0.00	$0.00	-$3.53M	-$5.75M
Research & Development	$109.65M	$117.60M	$64.60M	$49.06M
Selling, General & Admin	$70.26M	$77.50M	$53.18M	$39.16M
Operating Expenses	$179.91M	$195.10M	$117.78M	$88.22M
Operating Income	-$179.91M	-$195.10M	-$121.31M	-$93.97M
EBITDA	-$170.93M	-$181.42M	-$120.30M	$9.83M
Pretax Income	-$183.58M	-$190.13M	-$125.77M	$5.70M
Net Income	-$250.16M	-$113.72M	$136.00K	$5.70M
Diluted EPS	-46.20	-17.77	0.00	0.64
Diluted Shares	5.40M	6.40M	7.77M	8.87M

MCRB Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$163.03M	$127.97M	$30.79M	$45.77M
Receivables	$0.00	$0.00	$4.75M	$517.00K
Inventory	$0.00	$29.65M	—	—
Current Assets	$194.76M	$175.41M	$38.67M	$49.38M
Total Assets	$348.78M	$358.60M	$139.81M	$138.19M
Current Liabilities	$85.60M	$98.66M	$41.22M	$19.32M
Long-Term Debt	$50.59M	$101.54M	—	—
Total Debt	$162.59M	$198.78M	$91.64M	$82.97M
Total Liabilities	$338.00M	$403.46M	$126.03M	$93.97M
Retained Earnings	-$864.51M	-$978.24M	-$978.10M	-$972.40M
Shareholders' Equity	$10.78M	-$44.86M	$13.78M	$44.22M
Working Capital	$109.17M	$76.75M	-$2.55M	$30.05M

MCRB Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$228.82M	-$117.35M	-$148.61M	$1.12M
Capital Expenditure	-$9.82M	-$7.97M	-$380.00K	-$252.00K
Free Cash Flow	-$238.64M	-$125.33M	-$148.99M	$865.00K
Depreciation & Amortisation	$6.63M	$6.24M	$5.47M	$4.13M
Stock-Based Compensation	$25.48M	$34.10M	$20.97M	$10.84M
Investing Cash Flow	$82.43M	$10.58M	$142.29M	-$42.00K
Financing Cash Flow	$129.60M	$71.70M	-$90.37M	$13.90M
Net Change in Cash	-$16.79M	-$35.07M	-$96.69M	$14.97M

MCRB Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$789.00K	$358.00K	$736.00K
Cost of Revenue	$3.53M	$1.69M	$736.00K	$592.00K	$0.00	$0.00
Gross Profit	-$3.53M	-$1.69M	-$736.00K	$197.00K	$358.00K	$736.00K
Research & Development	$11.82M	$12.94M	$12.62M	$11.68M	$13.20M	$9.14M
Selling, General & Admin	$11.89M	$10.25M	$9.48M	$7.54M	$8.07M	$7.06M
Operating Expenses	$23.71M	$23.19M	$21.74M	$19.57M	$21.27M	$16.20M
Operating Income	-$27.24M	-$24.88M	-$22.48M	-$19.38M	-$20.91M	-$15.47M
EBITDA	-$26.16M	-$23.82M	-$21.43M	$81.24M	-$20.13M	-$14.80M
Pretax Income	$32.68M	-$19.86M	$8.20M	-$15.34M	-$19.91M	$4.58M
Net Income	$32.68M	-$19.86M	$8.20M	-$15.34M	-$19.91M	$4.58M
Diluted EPS	3.75	-2.27	0.94	—	-2.08	0.47
Diluted Shares	8.71M	8.74M	8.77M	—	9.58M	9.75M

MCRB Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$58.85M	$45.38M	$47.64M	$45.77M	$29.83M	$15.59M
Receivables	$4.38M	$1.16M	$777.00K	$517.00K	$233.00K	$25.27M
Current Assets	$66.08M	$48.69M	$51.53M	$49.38M	$31.84M	$42.35M
Total Assets	$164.18M	$143.80M	$143.47M	$138.19M	$117.62M	$101.59M
Current Liabilities	$31.32M	$30.94M	$22.43M	$19.32M	$19.34M	$20.03M
Total Debt	$89.55M	$87.43M	$85.25M	$82.97M	$80.50M	$56.64M
Total Liabilities	$113.72M	$110.85M	$99.78M	$93.97M	$91.12M	$67.05M
Retained Earnings	-$945.42M	-$965.27M	-$957.07M	-$972.40M	-$992.32M	-$987.74M
Shareholders' Equity	$50.47M	$32.95M	$43.70M	$44.22M	$26.50M	$34.53M
Working Capital	$34.76M	$17.75M	$29.10M	$30.05M	$12.49M	$22.32M

MCRB Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$26.91M	-$13.29M	$2.21M	-$14.71M	-$16.36M	-$22.39M
Capital Expenditure	-$34.00K	-$181.00K	-$8.00K	-$29.00K	—	—
Free Cash Flow	$26.88M	-$13.47M	$2.20M	-$14.74M	-$16.36M	-$22.39M
Depreciation & Amortisation	$1.08M	$1.06M	$1.04M	$954.00K	$781.00K	$670.00K
Stock-Based Compensation	$2.82M	$2.34M	$2.48M	$3.20M	$1.77M	$1.74M
Investing Cash Flow	-$34.00K	-$181.00K	-$8.00K	$181.00K	$0.00	$14.00K
Financing Cash Flow	$1.18M	$0.00	$61.00K	$12.66M	$428.00K	$1.72M
Net Change in Cash	$28.06M	-$13.47M	$2.26M	-$1.87M	-$15.93M	-$20.66M

Market Snapshot

About

Seres Therapeutics, Inc. is a microbiome therapeutics company developing bacterial consortia treatments for diseases including C. difficile infection and ulcerative colitis.